TY - JOUR
T1 - Contemporary treatment of borderline ovarian tumors
AU - Gershenson, David M.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1999
Y1 - 1999
N2 - In conclusion, the prognosis for women with stage I borderline tumors is excellent. Surgery alone is the recommended treatment. For young patients, fertility-sparing surgery is optimal, with a small percentage eventually developing tumor in the contralateral ovary. For patients with advanced stage borderline tumors, 10-30% will relapse and approximately 10% will die of tumor. This risk is clearly higher for those with invasive peritoneal implants. Several controversies exist, including the classification of advanced stage serous borderline tumors and the issue of postoperative treatment. Future studies involving larger series and molecular biomarkers will hopefully elucidate the biologic behavior and optimal therapy for this interesting group of tumors.
AB - In conclusion, the prognosis for women with stage I borderline tumors is excellent. Surgery alone is the recommended treatment. For young patients, fertility-sparing surgery is optimal, with a small percentage eventually developing tumor in the contralateral ovary. For patients with advanced stage borderline tumors, 10-30% will relapse and approximately 10% will die of tumor. This risk is clearly higher for those with invasive peritoneal implants. Several controversies exist, including the classification of advanced stage serous borderline tumors and the issue of postoperative treatment. Future studies involving larger series and molecular biomarkers will hopefully elucidate the biologic behavior and optimal therapy for this interesting group of tumors.
UR - http://www.scopus.com/inward/record.url?scp=0033025085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033025085&partnerID=8YFLogxK
U2 - 10.3109/07357909909021423
DO - 10.3109/07357909909021423
M3 - Article
C2 - 10099660
AN - SCOPUS:0033025085
SN - 0735-7907
VL - 17
SP - 206
EP - 210
JO - Cancer Investigation
JF - Cancer Investigation
IS - 3
ER -